Impact of 24-week dapagliflozin treatment on body weight, body composition, and cardiac risk indicators of patients with type-2 diabetes mellitus.
Pinar AkhanliSema Hepşenİsmail Emre ArslanHakan DüğerHayri BostanMuhammed KizilgulBekir UcanMustafa OzbekPublished in: Turkish journal of medical sciences (2023)
It was observed that dapagliflozin not only contributes to weight and fat loss but also has positive impacts on cardiovascular and atherosclerotic indicators.
Keyphrases
- body composition
- body weight
- end stage renal disease
- resistance training
- newly diagnosed
- ejection fraction
- bone mineral density
- adipose tissue
- peritoneal dialysis
- left ventricular
- randomized controlled trial
- patient reported outcomes
- atrial fibrillation
- high intensity
- combination therapy
- weight gain
- study protocol
- smoking cessation